Literature DB >> 8794823

Cardiac and vascular effects of long-term losartan treatment in stroke-prone spontaneously hypertensive rats.

P Gohlke1, W Linz, B A Schölkens, G Wiemer, T Unger.   

Abstract

In previous studies in stroke-prone spontaneously hypertensive rats (SHRSP), we demonstrated that early-onset, long-term angiotensin-converting enzyme inhibitor treatment improved cardiac function and metabolism and increased aortic cGMP content even at sub-antihypertensive doses. These effects could be prevented by bradykinin type 2 (B2) receptor blockade with icatibant. In the present study, we studied the effects of long-term oral treatment with the angiotensin type 1 (AT1) receptor antagonist losartan (30 mg/kg per day) on functional and biochemical parameters of the heart and on cGMP content in the aorta in SHRSP treated prenatally and subsequently up to the age of 20 weeks. Losartan prevented the development of hypertension and left ventricular hypertrophy. Cardiac function measured ex vivo in isolated perfused hearts was improved, as demonstrated by significant increases in left ventricular pressure (22.4%), differentiated left ventricular pressure (dP/dtmax) (35.1%), and coronary flow (38%). The release of the intracellular enzymes lactate dehydrogenase and creatine kinase and of lactate into the coronary effluent was reduced by 46.4%, 47.2%, and 63.6%, respectively. In myocardial tissue, the concentrations of glycogen and the energy-rich phosphates ATP and creatine phosphate were increased by 43.2%, 33.1%, and 42.4%, respectively, whereas lactate was decreased by 57.0%. The aortic tissue content of cGMP was increased fivefold. Our results demonstrate that chronic blockade of AT1 receptors with losartan improved cardiac function and metabolism and increased aortic cGMP content in SHRSP to an extent similar to that observed previously after long-term angiotensin-converting enzyme inhibitor treatment at a comparably antihypertensive dose. Prevention of hypertension and cardiac hypertrophy as well as stimulation of non-AT1 receptors are discussed to explain the cardiac and vascular actions of losartan.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8794823     DOI: 10.1161/01.hyp.28.3.397

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  6 in total

Review 1.  Genetic targeting of the renin-angiotensin system for long-term control of hypertension.

Authors:  Beverly L Metcalfe; Mohan Raizada; Michael J Katovich
Journal:  Curr Hypertens Rep       Date:  2002-02       Impact factor: 5.369

2.  Angiotensin II subtype AT1 receptor blockade prevents hypertension and renal insufficiency induced by chronic NO-synthase inhibition in rats.

Authors:  M Hropot; K H Langer; Gabriele Wiemer; H Grötsch; W Linz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-01-25       Impact factor: 3.000

3.  Different effects of losartan and moxonidine on endothelial function during sympathetic activation in essential hypertension.

Authors:  Michael N Doumas; Stella N Douma; Kostas M Petidis; Kostas V Vogiatzis; Ilias C Bassagiannis; Chris X Zamboulis
Journal:  J Clin Hypertens (Greenwich)       Date:  2004-12       Impact factor: 3.738

Review 4.  Vascular biology of ageing-Implications in hypertension.

Authors:  Adam Harvey; Augusto C Montezano; Rhian M Touyz
Journal:  J Mol Cell Cardiol       Date:  2015-04-17       Impact factor: 5.000

5.  Combination of β Adrenergic Receptor Block and Renin-Angiotensin System Inhibition Diminished the Angiotensin II-Induced Vasoconstriction and Increased Bradykinin-Induced Vasodilation in Hypertension.

Authors:  Diego Lezama-Martínez; Ignacio Valencia-Hernández; Jazmin Flores-Monroy; Luisa Martínez-Aguilar
Journal:  Dose Response       Date:  2017-11-12       Impact factor: 2.658

6.  Effects of losartan and atorvastatin on the development of early posttraumatic joint stiffness in a rat model.

Authors:  Andreas Baranowski; Ludwig Schlemmer; Katharina Förster; Ekaterina Slotina; Tim Mickan; Sebastian Truffel; Anja Klein; Stefan G Mattyasovszky; Alexander Hofmann; Ulrike Ritz; Pol M Rommens
Journal:  Drug Des Devel Ther       Date:  2019-07-30       Impact factor: 4.162

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.